Fei Su
Impact in
- Geriatrics and Gerontology top 0.1%
- Sirtuins and Resveratrol in Medicine
- Aging top 2%
Papers in
- Oncology 22
- Cancer Immunotherapy and Biomarkers 5
- Pancreatic and Hepatic Oncology Research 4
- Cancer-related Molecular Pathways 4
- Colorectal Cancer Treatments and Studies 4
- HER2/EGFR in Cancer Research 4
- Co-authors
- Delin ChenJianyuan LuoWei GuRobert J. SchneiderShin‐ichiro ImaiAnatoly NikolaevLeonard GuarenteMargherita Doria
- Journals
- Journal of Bacteriology (5 papers)Journal of Clinical Oncology (3 papers)Annals of Oncology (2 papers)Human Vaccines & Immunotherapeutics (2 papers)Frontiers in Oncology (2 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Fei Su
65 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Geriatrics and Gerontology 1.2k
- Aging 139
- Physiology 225
- Oncology 904
- Epidemiology 1.1k
Countries citing papers authored by Fei Su
This map shows the geographic impact of Fei Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Su more than expected).
Fields of papers citing papers by Fei Su
This network shows the impact of papers produced by Fei Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Su. The network helps show where Fei Su may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fei Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 5 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 5 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 11 | |
| 8 | 2022 | 1 | |
| 9 | 2022 | 2 | |
| 10 | 2022 | 1 | |
| 11 | 2021 | 7 | |
| 12 | 2021 | 12 | |
| 13 | 2021 | 18 | |
| 14 | 2021 | 1 | |
| 15 | 2021 | 5 | |
| 16 | 2018 | 32 | |
| 17 | 2014 | 1 | |
| 18 | 2014 | 20 | |
| 19 | Random study of Entecavir and Adefovir dipivoxil in patients with chronic hepatitis B. | 2010 | 2 |
| 20 | Deacetylation of p53 modulates its effect on cell growth and apoptosis Hit paper breakdown → | 2000 | 681 |
About Fei Su
Fei Su is a scholar working on Oncology, Biotechnology, Cancer Research, Epidemiology and Neurology, having authored 67 papers that have together received 3.8k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Pancreatic and Hepatic Oncology Research (4 papers), Cancer-related Molecular Pathways (4 papers), Neuroendocrine Tumor Research Advances (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Genomics and Phylogenetic Studies (4 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Geriatrics and Gerontology (1.2k citations), Aging (139 citations), Physiology (225 citations), Oncology (904 citations) and Epidemiology (1.1k citations). Fei Su has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Delin Chen, Jianyuan Luo, Wei Gu, Robert J. Schneider, Shin‐ichiro Imai, Anatoly Nikolaev, Leonard Guarente, Margherita Doria, Baoquan Liu and Yafang Zhang. Their work appears in journals such as Journal of Bacteriology, Journal of Clinical Oncology, Annals of Oncology, Human Vaccines & Immunotherapeutics and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.